$ASTH
Astrana Health, Inc. Stock $asth

$asth Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000162828021016083 Filed on August 06, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$175.6M	$165.2M
YoY Change	6.34%	27.0%
Cost Of Revenue	$136.2M	$136.1M
YoY Change	0.1%	34.25%
Gross Profit	$39.42M	$29.09M
YoY Change	35.52%	1.4%
Gross Profit Margin	22.45%	17.61%
Selling, General & Admin	$14.20M	$11.60M
YoY Change	22.41%	22.11%
% of Gross Profit	36.02%	39.88%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$4.234M	$4.320M
YoY Change	-1.99%	-3.02%
% of Gross Profit	10.74%	14.85%
Operating Expenses	$18.44M	$16.20M
YoY Change	13.8%	-85.95%
Operating Profit	$20.99M	$12.91M
YoY Change	62.62%	-12.37%
Interest Expense	$1.853M	$2.673M
YoY Change	-30.68%	759.49%
% of Operating Profit	8.83%	20.71%
Other Income/Expense, Net	$63.46M	$99.95M
YoY Change	-36.51%	68833.1%
Pretax Income	$84.45M	$112.9M
YoY Change	-25.17%	658.82%
Income Tax	$24.92M	$31.86M
% Of Pretax Income	29.51%	28.23%
Net Earnings	$12.66M	$7.044M
YoY Change	79.7%	98.7%
Net Earnings / Revenue	7.21%	4.26%
Basic Earnings Per Share	$0.29	$0.20
Diluted Earnings Per Share	$0.28	$0.19
COMMON SHARES
Basic Shares Outstanding	44.17M shares	36.07M shares
Diluted Shares Outstanding	45.83M shares	37.29M shares

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$364.5M	$270.1M
YoY Change	34.95%	401.11%
Cash & Equivalents	$177.3M	$152.4M
Short-Term Investments	$187.2M	$117.7M
Other Short-Term Assets	$12.19M	$11.20M
YoY Change	8.82%	-17.65%
Inventory
Prepaid Expenses
Receivables	$16.54M	$17.59M
Other Receivables	$4.562M	$15.92M
Total Short-Term Assets	$470.6M	$380.5M
YoY Change	23.65%	127.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$57.67M	$31.70M
YoY Change	81.91%	161.95%
Goodwill	$239.1M	$239.1M
YoY Change	0.02%	14.21%
Intangibles	$80.23M	$94.79M
YoY Change	-15.36%	-13.09%
Long-Term Investments	$37.37M	$26.82M
YoY Change	39.36%	-25.31%
Other Assets	$8.072M	$22.49M
YoY Change	-64.1%	1563.76%
Total Long-Term Assets	$423.9M	$452.7M
YoY Change	-6.36%	12.97%
TOTAL ASSETS
Total Short-Term Assets	$470.6M	$380.5M
Total Long-Term Assets	$423.9M	$452.7M
Total Assets	$894.4M	$833.2M
YoY Change	7.35%	46.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.19M	$10.43M
YoY Change	7.36%	118.61%
Accrued Expenses	$9.731M	$6.400M
YoY Change	52.05%	8.47%
Deferred Revenue	$29.59M	$3.061M
YoY Change	866.81%	-80.22%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$205.0K	$9.500M
YoY Change	-97.84%	9400.0%
Total Short-Term Liabilities	$128.1M	$152.5M
YoY Change	-16.01%	94.68%
LONG-TERM LIABILITIES
Long-Term Debt	$182.7M	$230.5M
YoY Change	-20.72%	410.99%
Other Long-Term Liabilities	$1.195M	$17.40M
YoY Change	-93.13%	38.1%
Total Long-Term Liabilities	$219.9M	$261.9M
YoY Change	-16.03%	210.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$128.1M	$152.5M
Total Long-Term Liabilities	$219.9M	$261.9M
Total Liabilities	$348.0M	$414.4M
YoY Change	-16.02%	154.76%
SHAREHOLDERS EQUITY
Retained Earnings	$95.58M	$43.00M
YoY Change	122.27%	100.26%
Common Stock	$44.00K	$36.00K
YoY Change	22.22%	3.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$401.4M	$207.0M
YoY Change
Total Liabilities & Shareholders Equity	$894.4M	$833.2M
YoY Change	7.35%	46.61%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	$12.66M	$7.044M
YoY Change	79.7%	98.7%
Depreciation, Depletion And Amortization	$4.234M	$4.320M
YoY Change	-1.99%	-3.02%
Cash From Operating Activities	$21.34M	$21.87M
YoY Change	-2.44%	-221.16%
INVESTING ACTIVITIES
Capital Expenditures	-$7.264M	-$180.0K
YoY Change	3935.56%	-35.71%
Acquisitions
YoY Change
Other Investing Activities	-$3.228M	$68.27M
YoY Change	-104.73%	-236.92%
Cash From Investing Activities	-$10.49M	$68.09M
YoY Change	-115.41%	-235.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-39.43M	-18.49M
YoY Change	113.23%	-158.81%
NET CHANGE
Cash From Operating Activities	21.34M	21.87M
Cash From Investing Activities	-10.49M	68.09M
Cash From Financing Activities	-39.43M	-18.49M
Net Change In Cash	-28.58M	71.47M
YoY Change	-139.99%	-294.48%
FREE CASH FLOW
Cash From Operating Activities	$21.34M	$21.87M
Capital Expenditures	-$7.264M	-$180.0K
Free Cash Flow	$28.60M	$22.05M
YoY Change	29.71%	-224.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001083446
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37392
	dei	Entity Registrant Name EntityRegistrantName	Apollo Medical Holdings, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4472349
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1668 S. Garfield Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	2nd Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Alhambra
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91801
	dei	City Area Code CityAreaCode	626
	dei	Local Phone Number LocalPhoneNumber	282-0288
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	AMEH
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55340095	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177287000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193470000	USD
CY2021Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	187206000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	67695000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16540000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7058000	USD
CY2021Q2	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	68767000	USD
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	49260000	USD
CY2021Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4562000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4297000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12188000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16797000	USD
CY2021Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	4000000	USD
CY2020Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	470550000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	338577000	USD
CY2021Q2	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	40738000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	29890000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	80227000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	86985000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	239053000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	239053000	USD
CY2021Q2	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	594000	USD
CY2020Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	480000	USD
CY2021Q2	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	0	USD
CY2020Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	4145000	USD
CY2021Q2	us-gaap	Equity Method Investments EquityMethodInvestments	37372000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	43292000	USD
CY2021Q2	ameh	Investment In Privately Held Entity That Does Not Report Net Asset Value InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue	896000	USD
CY2020Q4	ameh	Investment In Privately Held Entity That Does Not Report Net Asset Value InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue	37075000	USD
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	500000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16928000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18574000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8072000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18915000	USD
CY2021Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	423880000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	478909000	USD
CY2021Q2	us-gaap	Assets Assets	894430000	USD
CY2020Q4	us-gaap	Assets Assets	817486000	USD
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	53792000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	36143000	USD
CY2021Q2	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	9092000	USD
CY2020Q4	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	9642000	USD
CY2021Q2	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	59307000	USD
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	50330000	USD
CY2021Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2215000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4224000	USD
CY2021Q2	us-gaap	Dividends Payable Current DividendsPayableCurrent	536000	USD
CY2020Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	485000	USD
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	110000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	102000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2831000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3177000	USD
CY2021Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	205000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10889000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	128088000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	114992000	USD
CY2021Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	21242000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10959000	USD
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	249000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	311000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14513000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15865000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	182705000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	230211000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1195000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2021Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	219904000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	257346000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	347992000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	372338000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	141856000	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	114237000	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44246796	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42249137	shares
CY2021Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10885732	shares
CY2020Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12323164	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	44000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	305736000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	261011000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	95580000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	69771000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	401360000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	330824000	USD
CY2021Q2	us-gaap	Minority Interest MinorityInterest	3222000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	87000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	404582000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	330911000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	894430000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	817486000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	175638000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	165169000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	351696000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	330274000	USD
CY2021Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	136214000	USD
CY2020Q2	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	136079000	USD
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	276829000	USD
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	280283000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14199000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11556000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23663000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23390000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	4237000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	4628000	USD
	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	8434000	USD
	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	9330000	USD
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	154650000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	152263000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	308926000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	313003000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	20988000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	12906000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	42770000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	17271000	USD
CY2021Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3134000	USD
CY2020Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	834000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3812000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2888000	USD
CY2021Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2020Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	99647000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	99647000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	1853000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	2673000	USD
	us-gaap	Interest Expense InterestExpense	3376000	USD
	us-gaap	Interest Expense InterestExpense	5541000	USD
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	563000	USD
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	863000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	912000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1792000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	67886000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1282000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	69190000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1384000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	63462000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	99953000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	62914000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	100170000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	84450000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	112859000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	105684000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	117441000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24920000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31858000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31696000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	33453000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	59530000	USD
CY2020Q2	us-gaap	Profit Loss ProfitLoss	81001000	USD
	us-gaap	Profit Loss ProfitLoss	73988000	USD
	us-gaap	Profit Loss ProfitLoss	83988000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	46872000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	73957000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	48179000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	72892000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	12658000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	7044000	USD
	us-gaap	Net Income Loss NetIncomeLoss	25809000	USD
	us-gaap	Net Income Loss NetIncomeLoss	11096000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	330911000	USD
CY2021Q1	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	13698000	USD
CY2021Q1	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	75000	USD
CY2021Q1	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	342000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	144000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	37000	USD
CY2021Q1	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	4256000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1346000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	349687000	USD
CY2021Q2	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	12671000	USD
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	0	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q2	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	561000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1556000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	189000	USD
CY2021Q2	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	2450000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	40133000	USD
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	3769000	USD
CY2021Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1156000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	404582000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	192335000	USD
CY2020Q1	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	4147000	USD
CY2020Q1	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	301000	USD
CY2020Q1	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	722000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1058000	USD
CY2020Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	0	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	197961000	USD
CY2020Q2	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	7335000	USD
CY2020Q2	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q2	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	2283000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	852000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	236000	USD
CY2020Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	347000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	207848000	USD
	us-gaap	Profit Loss ProfitLoss	73988000	USD
	us-gaap	Profit Loss ProfitLoss	83988000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8434000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9330000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	741000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	658000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2902000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1910000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	83769000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-25000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3812000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2888000	USD
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	USD
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	99647000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	15723000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	1195000	USD
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	0	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	10283000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-4473000	USD
	us-gaap	Proceeds From Other Operating Activities ProceedsFromOtherOperatingActivities	189000	USD
	us-gaap	Proceeds From Other Operating Activities ProceedsFromOtherOperatingActivities	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9975000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6284000	USD
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	19508000	USD
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	11191000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	266000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-966000	USD
	ameh	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	-4613000	USD
	ameh	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	873000	USD
	ameh	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	1646000	USD
	ameh	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	1680000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	426000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5095000	USD
	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	8977000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16984000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3043000	USD
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-550000	USD
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-174000	USD
	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	11252000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2009000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	37681000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1698000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1247000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	31286000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12575000	USD
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	31000	USD
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	16500000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	117000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	ameh	Prepayment For Investment Purchase PrepaymentForInvestmentPurchase	4450000	USD
	ameh	Prepayment For Investment Purchase PrepaymentForInvestmentPurchase		USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	670000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1142000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1660000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	500000	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	52743000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7364000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	451000	USD
	ameh	Proceeds From Cash Received From Consolidation Of Variable Interest Entity ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity	3322000	USD
	ameh	Proceeds From Cash Received From Consolidation Of Variable Interest Entity ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1106000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9802000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	67150000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	21110000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	30187000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	238208000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2375000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	54000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	61000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4816000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2863000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2981000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	788000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	75000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0	USD
	ameh	Proceeds From Sale Of Noncontrolling Interest ProceedsFromSaleOfNoncontrollingInterest	38000	USD
	ameh	Proceeds From Sale Of Noncontrolling Interest ProceedsFromSaleOfNoncontrollingInterest	0	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	180000000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	40134000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	727000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-38167000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-30548000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16683000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	49177000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193970000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104010000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177287000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153187000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	23324000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	2507000	USD
	us-gaap	Interest Paid Net InterestPaidNet	2623000	USD
CY2021Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	50000	USD
CY2020Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	160000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	36179000	USD
	ameh	Cancellation Of Restricted Stock Awards CancellationOfRestrictedStockAwards	144000	USD
	ameh	Cancellation Of Restricted Stock Awards CancellationOfRestrictedStockAwards	0	USD
CY2021Q2	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	0	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177287000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177287000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	152441000	USD
CY2020Q2	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	746000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177287000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153187000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193470000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103189000	USD
CY2020Q4	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	500000	USD
CY2019Q4	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	746000	USD
CY2020Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	0	USD
CY2019Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	75000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193970000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104010000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. (“ApolloMed”) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (“NMM”) on December 8, 2017 (“2017 Merger”). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the “Company,” “we,” “us,” “our,” and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed’s subsidiaries and VIEs include management services organizations (“MSOs”), affiliated independent practice associations (“IPAs”), and a Next Generation Accountable Care Organization (“NGACO”). NMM and Apollo Medical Management, Inc. (“AMM”) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”), (ii) Alpha Care Medical Group, Inc. (“Alpha Care”), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (“Accountable Health Care”). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (“AMH”) and Southern California Heart Centers, a Medical Corporation (“SCHC”). The Company’s NGACO operates under the APA ACO, Inc. (“APAACO”) brand and participates in the Centers for Medicare & Medicaid Services (“CMS”) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program’s attribution-based risk-sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company’s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSOs and Affiliates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (“AMH”) and Southern California Heart Centers, a Medical Corporation (“SCHC”). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPAs and Affiliates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (“HMOs”) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. In accordance with relevant accounting guidance, AP-AMH is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the “AP-AMH Loan”). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the “Certificate of Determination”), AP-AMH is entitled to receive preferential, cumulative dividends (“Series A Dividends”) that accrue on a daily basis and that are equal to the sum of (i) APC’s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC’s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">APC purchased 15,015,015 shares of ApolloMed’s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed’s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed’s then outstanding shares will be voted by proxy given to ApolloMed’s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed’s stockholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the series of transactions described above, APC and AP-AMH entered into a Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term “Excluded Assets.” Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company’s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC’s ownership in ApolloMed was 19.77% at June 30, 2021 and 22.58% at December 31, 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed in March 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of June 30, 2021, APC owned 45.01% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (“APC-LSMA”) was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA’s sole </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group (“DMG”) and AHMC International Cancer Center, a Medical Corporation (“ICC”). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (“MMG”), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (“AMG”). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care’s capital stock that they did not already own (comprising 75%) for $7.3 million in cash.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (“MPP”), AMG Properties, LLC (“AMG Properties”), and ZLL Partners, LLC (“ZLL”) and a 50% interest in each of One MSO, LLC (“One MSO”), Tag-6 Medical Investment Group, LLC (“Tag 6”), and Tag-8 Medical Investment Group, LLC (“Tag 8”). These entities own buildings that are currently leased to tenants or vacant land with plans to lease the building in the future. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation, it was concluded that Tag 8 is a VIE and is consolidated by APC because APC has the ability to direct the activities that most significantly affect Tag 8’s economic performance. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC’s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the definitive proxy statement that ApolloMed filed with the Securities and Exchange Commission (the “SEC”) on July 31, 2019 (the “2019 Proxy Statement”), and consequently will not affect net income attributable to ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO</span></div>APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model of CMS in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	268200000	USD
CY2020Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	294900000	USD
CY2021Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	119900000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	36200000	USD
	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	83800000	USD
CY2021Q2	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain	83800000	USD
	ameh	Risk Pool Surplus Or Deficits Settlement Period After Performance Year RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear	P18M
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. </span></div>The consolidated statements of income present disaggregated revenue by service type.
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	175638000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	165169000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	351696000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	330274000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	107403000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	67200000	USD
CY2021Q2	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	120006000	USD
CY2021Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	294609000	USD
CY2021Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	1195000	USD
CY2021Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1195000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	115769000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	67637000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	58000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	183464000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	3	unit
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	239100000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	239100000	USD
CY2021Q2	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	9100000	USD
CY2020Q4	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	9600000	USD
	ameh	Payment Of Revenue Monthly Amount PaymentOfRevenueMonthlyAmount	8000000.0	USD
CY2021Q2	ameh	Payment Of Revenue PaymentOfRevenue	24300000	USD
	ameh	Payment Of Revenue PaymentOfRevenue	48100000	USD
CY2021Q2	ameh	Payment Of Revenue Revenue Recognized PaymentOfRevenueRevenueRecognized	14100000	USD
	ameh	Payment Of Revenue Revenue Recognized PaymentOfRevenueRevenueRecognized	31200000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	29600000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13000000.0	USD
	ameh	Equity Method Investments Consolidated EquityMethodInvestmentsConsolidated	3768000	USD
CY2021Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	177229000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	97002000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	80227000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	176529000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	89544000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	86985000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3700000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4100000	USD
CY2021Q2	us-gaap	Equity Method Investments EquityMethodInvestments	37372000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7500000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8200000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	7533000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	12906000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10842000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9830000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8758000	USD
CY2021Q2	ameh	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	30358000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	80227000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	43292000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3812000	USD
	ameh	Equity Method Investments Contribution EquityMethodInvestmentsContribution	1660000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11192000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9554000	USD
CY2021Q2	ameh	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	2600000	USD
CY2020Q4	ameh	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	3541000	USD
CY2021Q2	ameh	Subcontractor Ipa Payable SubcontractorIPAPayable	2356000	USD
CY2020Q4	ameh	Subcontractor Ipa Payable SubcontractorIPAPayable	1662000	USD
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	962000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1378000	USD
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	188000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	50000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	29594000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12988000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6900000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6970000	USD
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	53792000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	36143000	USD
	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	The Company’s medical liabilities consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,432)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,307 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	50330000	USD
CY2019Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	58725000	USD
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	158739000	USD
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	165571000	USD
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-1293000	USD
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	233000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	157446000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	165804000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	103302000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	326000	USD
CY2021Q2	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	59307000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	97112000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	45130000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	57470000	USD
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	148432000	USD
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	154582000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	-37000	USD
CY2020Q2	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	70273000	USD
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	187575000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	245705000	USD
CY2021Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	205000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10889000	USD
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4665000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4605000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	182705000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	230211000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	106000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	285000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	215000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	222000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	186747000	USD
CY2021Q2	us-gaap	Line Of Credit LineOfCredit	187575000	USD
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4700000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4600000	USD
	ameh	Stock Issued During Period Shares Merger StockIssuedDuringPeriodSharesMerger	143052	shares
	ameh	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	34158	shares
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1556000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	852000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2902000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1910000	USD
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	8000000.0	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	725864	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.25
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y9M
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3400000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	24437	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	23.24
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	9826	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.89
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	740475	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y4M6D
CY2021Q2	ameh	Class Of Warrants Or Right Grant In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue	0	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	36400000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	529638	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.36
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P2Y1M20D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	27100000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	120000	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1878126	shares
CY2020Q4	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants	10.39
CY2020	ameh	Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm	P1Y7M17D
CY2020Q4	ameh	Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue	14800000	USD
	ameh	Number Of Warrants Granted NumberOfWarrantsGranted	0	shares
	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Grant In Period ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod	0
	ameh	Number Of Warrants Exercised NumberOfWarrantsExercised	474506	shares
	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Exercised In Period ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod	10.15
CY2021Q2	ameh	Class Of Warrants Or Right Exercises In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue	8100000	USD
	ameh	Class Of Warrant Or Right Cancelled In Period ClassOfWarrantOrRightCancelledInPeriod	17803	shares
	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants Forfeited In Period ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod	9.72
CY2021Q2	ameh	Class Of Warrants Or Right Forfeitures In Period Aggregate Intrinsic Value ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue	0	USD
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1385817	shares
CY2021Q2	ameh	Class Of Warrants Or Right Weighted Average Exercise Price Of Warrants ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants	10.49
	ameh	Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm	P1Y5M8D
CY2021Q2	ameh	Class Of Warrants Or Right Outstanding Aggregate Intrinsic Value ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue	72500000	USD
	ameh	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod	474506	shares
	ameh	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod	273900	shares
	ameh	Warrant Issued During Period Value Stock Options Exercised WarrantIssuedDuringPeriodValueStockOptionsExercised	4800000	USD
	ameh	Warrant Issued During Period Value Stock Options Exercised WarrantIssuedDuringPeriodValueStockOptionsExercised	2600000	USD
	ameh	Percentage Of Financial Guarantee Benchmark Amount PercentageOfFinancialGuaranteeBenchmarkAmount	0.02
CY2021Q2	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	12588000	USD
CY2020Q2	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	5815000	USD
	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	25533000	USD
	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	17607000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.300
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.285
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.20
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44165264	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36071604	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45828802	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37285585	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.58
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43255901	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36040936	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44746761	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37296913	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36040936	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44746761	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44165264	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36071604	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45828802	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37285585	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43255901	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37296913	shares
CY2021Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2021Q2	us-gaap	Lessee Finance Lease Renewal Term1 LesseeFinanceLeaseRenewalTerm1	P10Y
	ameh	Lessee Finance Lease Termination Period If Applicable LesseeFinanceLeaseTerminationPeriodIfApplicable	P1Y
	ameh	Lessee Operating Lease Termination Period If Applicable LesseeOperatingLeaseTerminationPeriodIfApplicable	P1Y
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	400000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	400000	USD
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1263000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1446000	USD
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	27000	USD
CY2020Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	35000	USD
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	500000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	400000	USD
CY2021Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	3000	USD
CY2020Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000	USD
CY2021Q2	us-gaap	Sublease Income SubleaseIncome	280000	USD
CY2020Q2	us-gaap	Sublease Income SubleaseIncome	226000	USD
CY2021Q2	us-gaap	Lease Cost LeaseCost	1013000	USD
CY2020Q2	us-gaap	Lease Cost LeaseCost	1259000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	2515000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	3388000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	54000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	61000	USD
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1293000	USD
CY2020Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	1333000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	7000	USD
	us-gaap	Sublease Income SubleaseIncome	473000	USD
	us-gaap	Sublease Income SubleaseIncome	360000	USD
	us-gaap	Lease Cost LeaseCost	2102000	USD
	us-gaap	Lease Cost LeaseCost	3096000	USD
CY2021Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	3000	USD
CY2020Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000	USD
CY2021Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27000	USD
CY2020Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	35000	USD
CY2021Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2907000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	3149000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	2880000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	6000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	377000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3929000	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	7000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	54000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	61000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7652000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M21D
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y21D
CY2021Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M1D
CY2020Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M1D
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0610
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0610
CY2021Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0300
CY2020Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0300
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	119000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3303000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2042000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	60000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3529000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	119000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2940000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	79000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2648000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2021Q2	ameh	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	6811000	USD
CY2021Q2	ameh	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	0	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21273000	USD
CY2021Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	18000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	17344000	USD
CY2021Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	359000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2831000	USD
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	110000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14513000	USD
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	249000	USD

Files In Submission

Name	View Source	Status
0001628280-21-016083-index-headers.html	Edgar Link	pending
0001628280-21-016083-index.html	Edgar Link	pending
0001628280-21-016083.txt	Edgar Link	pending
0001628280-21-016083-xbrl.zip	Edgar Link	pending
ameh-20210630.htm	Edgar Link	pending
ameh-20210630.xsd	Edgar Link	pending
ameh-20210630_cal.xml	Edgar Link	unprocessable
ameh-20210630_def.xml	Edgar Link	unprocessable
ameh-20210630_htm.xml	Edgar Link	completed
ameh-20210630_lab.xml	Edgar Link	unprocessable
ameh-20210630_pre.xml	Edgar Link	unprocessable
ex102021063010-q.htm	Edgar Link	pending
ex31120210630110-q.htm	Edgar Link	pending
ex3122021063010-q.htm	Edgar Link	pending
ex3132021063010-q.htm	Edgar Link	pending
ex322021063010-q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASTH
Astrana Health, Inc. Stock $asth

2021 Q2 Form 10-Q Financial Statement

#000162828021016083 Filed on August 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH Astrana Health, Inc. Stock $asth

2021 Q2 Form 10-Q Financial Statement

#000162828021016083 Filed on August 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH
Astrana Health, Inc. Stock $asth